Day: July 17, 2021

VANCOUVER, British Columbia, July 17, 2021 (GLOBE NEWSWIRE) — Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (“Core One” or the “Company”) is pleased to announce that Dr. Robert E.W. Hancock, the Company’s Chairman, and CEO of its wholly owned subsidiary Vocan Biotechnologies Inc. (“Vocan”) will be presenting at a Company hosted Virtual Town Hall meeting on Wednesday, August 4, 2021 at 1:30 p.m. PST/ 4:30 p.m. ET/ 22:30 p.m. CET. The Virtual Town Hall event will comprise of a presentation by Dr. Hancock on the status of Vocan’s production of biosynthetic psilocybin and will include live video from the Company’s operating laboratory in Victoria, British Columbia. Dr. Hancock will also be answering questions from investors. “2021 has been a significant year for Core One Labs, and our teams have been very...

SHANGHAI, China, July 16, 2021 (GLOBE NEWSWIRE) — ECMOHO Limited (Nasdaq: MOHO) (“ECMOHO” or the “Company”), a leading integrated solutions provider in the health and wellness market in China, is pleased today to announce a strategic cooperation agreement with well-known South Korean pharmaceutical company, ChongKunDang Group (hereafter referred to as “CKD”), in providing global marketing and multichannel sales for one-stop retail solutions for CKD’s health products in China. With advanced equipment and cutting-edge technology as its foundation, CKD will be able to provide Chinese consumers with high-quality, diversified healthcare products, including probiotics, via ECMOHO’s established and extensive domestic distribution channels. ECMOHO, as a leading online retail service provider of health products in China, has cooperated...

No Action Needs to be Taken by Monmouth Shareholders at This Time HOLMDEL, N.J., July 16, 2021 (GLOBE NEWSWIRE) — Monmouth Real Estate Investment Corporation (NYSE: MNR, “Monmouth” or “the Company”) today announced that it received an amendment to the unsolicited acquisition proposal it previously received on July 8, 2021 from a certain large private investment firm. The amendment to the proposal reflects an increase of $0.18 per share in the consideration that would be paid for each share of Monmouth Common Stock, resulting in a net cash consideration of $18.88 per share, reflecting a stated purchase price of $19.51 per share reduced by the termination fee of approximately $62.2 million, or $0.63 per share, if Monmouth terminates the merger agreement it previously entered into with Equity Commonwealth (“EQC”) in accordance with...